Project portfolio
NOSO-502 BVL-GSK098 Gepotidacin tissue distribution ERA4TB-01 ERA4TB-02 ERA4TB-03 ERA4TB-04 ERA4TB-06 ERA4TB-09 ERA4TB-10 BC1 back up RespiriTB RespiriNTM


Description: NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.

Mode of Action (MoA): Inhibition bacterial ribosome


Description: Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line tuberculosis treatments.

Mode of Action (MoA): Transcriptional modulator

Gepotidacin tissue distribution

Description: Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.

Mode of Action (MoA): Topoisomerase type II inhibitor


Description: Molecule targeting cholesterol catabolism of mycobacteria.

Mode of Action (MoA): Cholesterol catabolism of mycobacteria


Description: Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.

Mode of Action (MoA): Mycobacterium tuberculosis tryptophan synthase


Description: Compounds targeting energy metabolism (electron chain transport).

Mode of Action (MoA): Energy metabolism


Description: Compound targeting lysine transfer RNA synthetase, which is an essential gene as assessed by transposon mutagenesis.

Mode of Action: Lysine transfer RNA synthase


Description: Mycobacterial membrane protein Large 3 (Mmpl3) compounds with potent in vitro inhibitory and bactericidal activity against Mycobacterium tuberculosis.

Mode of Action: Mmpl3


Natural product analogs active against Mycobacterium tuberculosis.


Description: Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1).

Mode of Action (MoA): DprE1

BC1 back up

Description: Lead optimisation program on BC1 inhibitors.

Mode of Action (MoA): BC1


Description: Mycothione reductase (Mtr) target exploration.

Mode of Action (MoA): Mtr


Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.